Essentials: Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson

About this video

Psychedelic researcher Dr. Matthew Johnson explains that psychedelic is more a cultural than a pharmacological label spanning several drug classes. Dr. Johnson describes classic psychedelics such as LSD, psilocybin, DMT, and mescaline as agonists or partial agonists at the serotonin 2A receptor, divided chemically into tryptamine and phenethylamine structures. He places NMDA antagonists such as ketamine in a separate class, and MDMA in a class of its own as an entactogen or empathogen. On therapeutic effects for depression, Dr. Johnson offers educated speculation that the common denominator may be persisting changes in self-representation, the model a person holds of themselves in the world. He also treats claims that psychedelics repair neurological injury cautiously, noting rodent neuroplasticity data and human anecdotes but emphasizing it is early days.

Key takeaways

• Dr. Johnson says classic psychedelics act as agonists or partial agonists at the serotonin 2A receptor.
• Dr. Johnson classifies ketamine-type compounds separately as NMDA antagonists.
• Dr. Johnson describes MDMA as an entactogen in a class by itself.
• Dr. Johnson speculates therapeutic benefit may involve persisting changes in self-representation.
• Dr. Johnson cautions that claims of psychedelics repairing brain injury rest on early, exploratory evidence.

Episode details: published July 24, 2025 · 98.8K views · 34:48 long. Summary written by Self Growth Videos from the episode itself. The science and protocols described are Andrew Huberman’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices.

← Previous: Health Effects & Risks of Kratom, Opioids & Other Natural Occurring Medicines | Dr. Chris McCurdy · Next: Male vs. Female Brain Differences & How They Arise From Genes & Hormones | Dr. Nirao Shah →

All Andrew Huberman videos · Andrew Huberman profile · Huberman Lab (official site)